CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Reminder - The CTS Reentry form, CTS-00172, will be updated on Monday July 2, 2018. It's posted ...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....